Janux Therapeutics, Inc.

JANX Healthcare Biotechnology

Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.

16.49 0.83 −4.79%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
−7.8×
Dividend yield
—
F-score
2/9
Altman Z
11.61
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 — 0.00 0.00
P/S ratio
78.40 — 61.46 40.28
P/FCF ratio
0.00 — 0.00 0.00
P/Operating CF
(117.91) — (70.60) 77.44
P/B ratio
1.55 — 0.93 1.04
Price to Tangible BV
1.55 — 0.93 1.04
EV/Sales
27.25 — (6.02) (0.17)
EV/EBITDA
0.00 — 0.50 0.03
EV/Operating CF
(7.48) — 1.10 0.10
EV/FCF
(7.38) — 1.09 0.10
Quick Ratio
35.54 38.67 16.83 16.14
Current Ratio
35.86 39.04 17.01 16.35
Net Debt/EBITDA
25.12 21.26 26.30 28.46
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.02 0.00 0.01 0.02
Operating CF/Net income
0.53 0.89 0.51 (0.57)
Capex/Depreciation
0.02 0.03 0.13 0.08
Research and Development Expense of Revenue
346.29% 0.00% 718.27% 301.88%
Selling, General and Administrative Expense of Revenue
106.22% 0.00% 298.23% 106.78%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
90.44% 0.00% 248.30% 88.26%
Graham Net Nets
0.63 — 1.05 0.93
Graham Number
0.00 — 0.00 0.00
Earnings Yield
(6.87%) — (13.24%) (10.68%)
Free Cash Flow Yield
(4.71%) — (9.01%) (4.34%)
Revenue per Share
0.16 0.00 0.06 0.16
Operating CF per Share
(0.21) (0.46) (0.20) 0.20
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.21) (0.46) (0.20) 0.20
Cash per Share
15.95 15.60 15.26 15.43
Shareholders Equity per Share
15.74 15.44 15.02 14.74
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
15.74 15.44 15.02 14.74
Free Cash Flow
(12.95) (28.65) (12.61) 12.28
Working Capital
970.26 950.89 943.13 923.19
Capital Expenditures
(0.09) (0.11) (0.27) (0.20)
Net Current Asset Value
949.88 931.14 915.36 903.67
EV/EBIT
0.00 — 0.54 0.03
Capex to Sales
0.01 0.00 0.07 0.02
Price to Operating Income
0.00 — 0.00 0.00
Other line items
Average Receivables
— — 18.25 0.92
Average Payables
2.93 4.50 2.86 3.25
Average Assets
859.89 1,031.54 1,039.50 1,019.93
Average Common Equity
816.33 989.80 977.00 959.25

Fold the line items

Columns are period end dates